NANOINK IMAGING--MAKING DISEASE VISIBLE

NanoInk Imaging, a spin-out of Rutgers University, develops, manufactures and commercializes novel contrast agents aimed at drug discovery workflows and clinical interventions.

​

These contrast agents offer enhanced tissue transparency, deeper tissue illumination potential, and molecular targeting of cell surface markers.

​

The first application for NanoInk is acceleration of pre-clinical oncology drug development pipelines by enabling researcher to observe tumors in animal models with an unprecedented level of detail, including immuno-oncology and liquid tumor studies.

The second application is in Cancer Surgery, where our contrast agents will enable surgeons to visualize tumor margins in real-time and reduce the need for repeat surgeries.

​

​